N-[3-[2-(2-hydroxyethoxy)phenyl]propyl]carbamic acid 1,1-dimethylethyl ester | 811865-67-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-[3-[2-(2-hydroxyethoxy)phenyl]propyl]carbamic acid 1,1-dimethylethyl ester
• 英文别名: tert-butyl N-[3-[2-(2-hydroxyethoxy)phenyl]propyl]carbamate
• CAS: 811865-67-5
• 化学式: C₁₆H₂₅NO₄
• 分子量: 295.379
• InChiKey: DUOLMORTLXQDTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[3-[2-(2-hydroxyethoxy)phenyl]propyl]carbamic acid 1,1-dimethylethyl ester 、 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到
  参考文献：
  名称：

  Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids

  摘要：

  Novel, potent small molecule motilin receptor antagonists are described. These peptidomimetic macrocycles are composed of a tripeptide cyclized backbone-to-backbone with a nonpeptidic tether and bear new unnatural amino acids containing basic side chains. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.043

文献信息

• MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME
  申请人：Hoveyda Hamid

  公开号：US20080194672A1

  公开（公告）日：2008-08-14

  The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，可以作为生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、骨骼疾病、遗传疾病、过度增生性疾病和炎症性疾病。
• Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
  申请人：Hoveyda Hamid R.

  公开号：US20110105389A1

  公开（公告）日：2011-05-05

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.

  本发明提供了新型构象定义的大环化合物，已被证明是生长激素分泌素受体（GRLN，生长激素分泌素受体，GHS-R1a及其亚型、异构体和/或变种）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的拮抗剂或逆向激动剂，以及用于治疗和预防一系列医学疾病，包括但不限于代谢和/或内分泌紊乱、肥胖和与肥胖相关的疾病、食欲或进食紊乱、成瘾紊乱、心血管疾病、胃肠道疾病、遗传疾病、过度增殖性疾病、中枢神经系统疾病和炎症性疾病。
• MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES
  申请人：Marsault Éric

  公开号：US20120270807A1

  公开（公告）日：2012-10-25

  The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.

  本发明涉及新型大环化合物及其盐，它们能结合和/或抑制丝氨酸蛋白酶酶。本发明还涉及这些化合物的中间体，含有这些化合物的制药组合物以及使用这些化合物的方法。这些化合物可用于治疗和预防一系列疾病指标，包括增生性疾病，特别是那些以肿瘤转移为特征的疾病，炎症性疾病，皮肤和组织疾病，心血管疾病，呼吸系统疾病和病毒感染。
• METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES
  申请人：Marsault Éric

  公开号：US20120270769A1

  公开（公告）日：2012-10-25

  The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.

  本发明涉及新型大环化合物及其盐，这些化合物与/或抑制丝氨酸蛋白酶酶的结合，并使用这些化合物的方法。本发明还涉及这些化合物的中间体、含有这些化合物的制药组合物以及使用它们的方法。这些化合物可用作治疗和预防一系列疾病指标的治疗剂，包括高增殖性疾病，特别是肿瘤转移、炎症性疾病、皮肤和组织疾病、心血管疾病、呼吸系统疾病和病毒感染。
• tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
  申请人：Tranzyme Pharma, Inc.

  公开号：EP2644618A1

  公开（公告）日：2013-10-02

  The present invention relates to intermediates of conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the ghrelin (growth hormone secretagogue) receptor including GHS-R1a and subtypes, isoforms and/or variants thereof and the use of these interemdaites to prepare said macrocyclic compounds.

  本发明涉及与胃泌素（生长激素分泌物）受体（包括 GHS-R1a 及其亚型、同工型和/或变体）结合和/或作为其功能调节剂的构象定义大环化合物的中间体，以及使用这些中间体制备所述大环化合物。